Alluvi tirzepatide appears to have emerged as a promising therapeutic agent for the management of metabolic disorders. This preclinical evaluation investigated the efficacy and tolerability of tirzepatide 40mg in in vivo models of metabolic syndrome. The experiments demonstrated that tirzepatide 40mg markedly improved glycemic control and decreased